Nicholas J. Vogelzang, MD, FASCO, FACP:This is a 76-year-old man who presented with urinary outflow symptoms and back pain to his urologist. He had a digital rectal exam showing a clearly abnormal rectala T3 or T4; the urologist referred him for biopsy, which revealed a Gleason grade group 4, or what we call a grade group 4—Gleason 8 prostate cancer in 9 of 12 cores. Preoperatively his PSA [prostate-specific antigen] was 85. His testosterone was noncastrate at 300. He had a bone scan and a CT scan showing multiple bone metastases and no soft tissue or lymph node involvement.
Using the data from STAMPEDE and LATITUDE trials, the patient was treated with LHRH [luteinizing hormone-releasing hormone] agonist therapy and abiraterone. The patient had a dramatic PSA and clinical and symptomatic response; his PSA dropped to undetectable. He felt very well, and as expected his testosterone also progressed to a very low level. This response lasted for about 3 years, and then at around that time his PSA began to slowly climbinitially from a 0.1 to 0.2, then with a doubling time of about 3 to 4 months—ultimately reaching a level of around 5, after which he became slightly symptomatic: His appetite was decreasing and fatigue increasing; he didn’t describe bone pain per se, but he did say, “Well, I’m needing a little bit more aspirin or Advil,” and I started to talk to him about stopping abiraterone and moving on to radium-223 [dichloride; Xofigo].
Transcript edited for clarity.
Hormone Sensitive mPC progressing to mCRPC
March 2015
H&P:
Imaging:
March 2018
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More